144 related articles for article (PubMed ID: 36970070)
1. CD25
Chen Z; Tong L; Neo SY; Li S; Gao J; Schlisio S; Lundqvist A
Oncoimmunology; 2023; 12(1):2175517. PubMed ID: 36970070
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.
Gowda A; Ramanunni A; Cheney C; Rozewski D; Kindsvogel W; Lehman A; Jarjoura D; Caligiuri M; Byrd JC; Muthusamy N
MAbs; 2010; 2(1):35-41. PubMed ID: 20081380
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
5. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
6. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
8. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.
Smyth MJ; Teng MW; Swann J; Kyparissoudis K; Godfrey DI; Hayakawa Y
J Immunol; 2006 Feb; 176(3):1582-7. PubMed ID: 16424187
[TBL] [Abstract][Full Text] [Related]
9. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.
Bergmann C; Wild CA; Narwan M; Lotfi R; Lang S; Brandau S
Eur J Immunol; 2011 Dec; 41(12):3564-73. PubMed ID: 21905023
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma.
Chang WC; Li CH; Chu LH; Huang PS; Sheu BC; Huang SC
Int J Gynecol Cancer; 2016 Jan; 26(1):156-62. PubMed ID: 26512789
[TBL] [Abstract][Full Text] [Related]
11. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
12. The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells.
Sewgobind VD; Quaedackers ME; van der Laan LJ; Kraaijeveld R; Korevaar SS; Chan G; Weimar W; Baan CC
Am J Transplant; 2010 Aug; 10(8):1785-95. PubMed ID: 20626385
[TBL] [Abstract][Full Text] [Related]
13. Low circulating CD4(+) CD25(+) Foxp3(+) T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure.
Winger EE; Reed JL
Am J Reprod Immunol; 2011 Oct; 66(4):320-8. PubMed ID: 21314851
[TBL] [Abstract][Full Text] [Related]
14. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
15. Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.
Vyth-Dreese FA; Sein J; van de Kasteele W; Dellemijn TA; van den Bogaard C; Nooijen WJ; de Gast GC; Haanen JB; Bex A
Clin Exp Immunol; 2010 Dec; 162(3):447-59. PubMed ID: 20942806
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
17. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro.
Yates J; Rovis F; Mitchell P; Afzali B; Tsang J; Garin M; Lechler RI; Lombardi G; Garden OA
Int Immunol; 2007 Jun; 19(6):785-99. PubMed ID: 17545278
[TBL] [Abstract][Full Text] [Related]
18. Blood CD4
Liao J; Li Y; Li X; Su X; Peng J; Xiao N; Fan X; Chen H; Lu G; Lin G; Cheng L; Gong F
Int Immunopharmacol; 2022 Sep; 110():108960. PubMed ID: 35759810
[TBL] [Abstract][Full Text] [Related]
19. Human renal-cell carcinoma cells are able to activate natural killer cells.
Hayakawa K; Morita T; Augustus LB; von Eschenbach AC; Itoh K
Int J Cancer; 1992 May; 51(2):290-5. PubMed ID: 1533204
[TBL] [Abstract][Full Text] [Related]
20. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
